The list identifies the most influential experts, who are among the 1% most cited in their speciality in several areas of knowledge.

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.

The award is a recognition for his significant contribution to the development of research in multiple sclerosis within the Catalan Institute of Health.

A study, led by Vall d'Hebron, identifies what type of information patients need to develop a web platform that will be useful to them when involving- se in making decisions about their treatment.

The Cardiovascular Diseases and Neurovascular Diseases groups at VHIR will investigate new therapeutic strategies for heart failure, nanomedicine in stroke and the prevention of cardiovascular toxicity in the case of oncological treatments.

After carrying out a first feasibility trial in collaboration with the Assisted Reproduction Section of the Vall d'Hebron Hospital, Manina Medtech is moving towards a pilot trial in IVF patients.

The evaluation committee has highlighted that VHIR has experienced a positive evolution in the last evaluation period.

The funds will enable the recruitment and retention of young talent, as well as the development of a new epigenetic drug

Researchers have used an innovative protocol to identify people with this autoimmune disease who have a higher risk of cancer.

As part of the initiative, WikiTropica, a tool that provides health professionals with up-to-date information on infectious and tropical diseases, has been launched.

This strategy protects almost two thirds of patients. It also reduces the waiting time between vaccination and initiation of immune suppressive treatment.

The aim is to make visible the attractiveness of VHIR as a place to work highlighting the unique opportunities it offers for biomedical research professionals at national and international level.

The initiative, coordinated by Dr. Pablo Velasco and Dr. Jose Luis Fuster, aims to bring innovation closer to patients and promote research projects in this disease.

This initiative of the ”la Caixa” Foundation offers the selected entrepreneurial scientists financial support and support through individual mentoring and training.

The project aims to test the HIPRA vaccine against COVID-19 in children (including adolescents) and immunocompromised people.

The European network EUPertStrain celebrates its annual meeting, focused on the study of the evolution of Bordetella pertussis, the bacterium responsible for this disease that can be very serious in children under one year.

The ability to be able to diagnose and differentiate both diseases as early as possible is fundamental to impact and stop the evolution of the disease before irreversible damage occurs.

The meeting, in which Dr. Pere Soler participated, showed the results of the first year with the description of new genetic defects associated with severe forms of COVID-19 and novelties in the detection of autoantibodies against interferons.

The members of the commission advise VHIR on financial investments selflessly.

The book is the culmination of the last ten years of research by Dr Gregori, Dr Quer and Dr Rodríguez-Frías in the Viral Hepatitis laboratory

More than 400 students have completed this program to train in research aimed at finding solutions to people's health problems.

The study shows that blocking the KLRG1 receptor helps to recover the activity of the natural killer cells of the immune system and reactivate the virus reservoir to fight infection.

On World Cancer Research Day, we highlight the oncology research model of the Vall d'Hebron Campus that allows laboratory results to be transferred as quickly as possible to clinical practice.

The Clinical and Translational Bioinformatics Group at VHIR has been responsible for the computational analysis of two international genetic studies led by the Children's Hospital of Philadelphia.